eXpanded (PrEPX) is a new study that will expand the provision of PrEP to 3,200 Victorians who have a high chance of acquiring HIV. Alfred Health is responsible for conducting the study.

WHO defines pre-exposure prophylaxis (PrEP) as the use of oral tenofovir disoproxil fumarate (TDF) or co-formulated TDF/emtricitabine (TDF/FTC) or co-formulated TDF/lamivudine (TDF/3TC) by HIV …

Evaluation of preexposure (PrEP) eligibility criteria, using sexually transmissible infections as markers of human immunodeficiency virus (HIV) risk at enrollment in PrEPX, a large Australian HIV PrEP trial.

HIV pre‐exposure prophylaxis (PrEP), the use of HIV treatment medication by people at risk of HIV to reduce their risk of acquisition, has emerged over recent years as a highly‐effe­ctive HIV prevention tool.

Background: Pre-exposure prophylaxis (PrEP) is the use of HIV anti-retroviral therapy to prevent HIV transmission in people at high risk of HIV acquisition. PrEP is highly efficacious when taken either …

Jul 26, 2016 · The PrEPX Study enrolled over 5,000 participants between 2016 and 2018 in Victoria, South Australia and Tasmania. Participants were at risk of HIV infections and received daily …

Apr 9, 2019 · Importance: Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure …

May 29, 2018 · PrEPX is a prospective, population-level intervention study, designed to emulate “real world” conditions to reflect the likely clinical scenario were tenofovir and emtricitabine to become …

Australia is considered to be a leading country in the provision of PrEP to populations at risk of HIV infection. The current national HIV strategy includes an aim of increasing to 75% the proportion of …

The PrEPX study sought to provide PrEP to 2600 people at high risk of HIV in Victoria, Australia, with the primary aim of reducing HIV transmissions in Victorian MSM by 30% and in the entire Victorian …